강황 추출물의 비알코올성 지방간 질환 개선 효과
Improvement Effect of Non-alcoholic Fatty Liver Disease by Curcuma longa L. Extract
1
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Background: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease associated with multiple metabolic disorders. The medicinal plant Curcuma longa L. is widely distributed in Asia and has been used to treat a spectrum diseases in clinical practice. To date, there are inadequate reports of the effects of C. longa 50% EtOH extract (CE) on NAFLD. Therefore, in this study, we evaluate the CE on an NAFLD animal and elucidate the mechanism of action. Methods and Results: C57BL/6J mice fed a methionine-choline deficient diet (MCD) were treated with CE or milk thistle, and changes in inflammation and stetosis were assessed. Experimental animals were divided into six group (n = 10); Normal, MCD, MCD + CE 50 ㎎/㎏/day (CE 50), MCD + CE 100 ㎎/㎏/day (CE 100), MCD + CE 150 ㎎/㎏/day (CE 150), and the Control, MCD + Milk thistle 150 ㎎/㎏/day (MT 150). Body weight, liver weight, liver function, and histological changes were assessed in experimental animals. Quantitative real-time polymerase chain reaction and western blot analyses were performed on samples collected after 4 weeks of treatment. We observed that CE administration improved MCD-diet-induced lipid accumulation, and triglyceride (TG) and total cholesterol (TC) levels in serum. Treatment with CE also decreased hepatic lipogenesis through modulation of the sterol regulatory element binding protein- 1 (SREBP-1), CCAAT-enhancer binding protein α (C/EBPα), fatty acid synthase (FAS), and peroxisome proliferator-activated receptor γ (PPARγ) expresion. In addition, the use of CE increased adenosine monophosphate-activated protein kinase (AMPK) phosphorylation and inhibited the up-regulation of toll-like receptor (TLR)-2 and TLR-4 signaling and the production of inflammatory mediators. Conclusions: In this report, we observed that CE regulated lipid accumulation in an MCD dietinduced NAFLD model by decreasing lipogenesis. These data suggeste that CE could effectively protect mice against MCD-induced NAFLD, by inhibiting the TLR-2 and TLR-4 signaling cascades.
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease associated with multiple metabolic disorders. The medicinal plant Curcuma longa L. is widely distributed in Asia and has been used to treat a spectrum diseases in clinical practice. To date, there are inadequate reports of the effects of C. longa 50% EtOH extract (CE) on NAFLD. Therefore, in this study, we evaluate the CE on an NAFLD animal and elucidate the mechanism of action. Methods and Results: C57BL/6J mice fed a methionine-choline deficient diet (MCD) were treated with CE or milk thistle, and changes in inflammation and stetosis were assessed. Experimental animals were divided into six group (n = 10); Normal, MCD, MCD + CE 50 ㎎/㎏/day (CE 50), MCD + CE 100 ㎎/㎏/day (CE 100), MCD + CE 150 ㎎/㎏/day (CE 150), and the Control, MCD + Milk thistle 150 ㎎/㎏/day (MT 150). Body weight, liver weight, liver function, and histological changes were assessed in experimental animals. Quantitative real-time polymerase chain reaction and western blot analyses were performed on samples collected after 4 weeks of treatment. We observed that CE administration improved MCD-diet-induced lipid accumulation, and triglyceride (TG) and total cholesterol (TC) levels in serum. Treatment with CE also decreased hepatic lipogenesis through modulation of the sterol regulatory element binding protein- 1 (SREBP-1), CCAAT-enhancer binding protein α (C/EBPα), fatty acid synthase (FAS), and peroxisome proliferator-activated receptor γ (PPARγ) expresion. In addition, the use of CE increased adenosine monophosphate-activated protein kinase (AMPK) phosphorylation and inhibited the up-regulation of toll-like receptor (TLR)-2 and TLR-4 signaling and the production of inflammatory mediators. Conclusions: In this report, we observed that CE regulated lipid accumulation in an MCD dietinduced NAFLD model by decreasing lipogenesis. These data suggeste that CE could effectively protect mice against MCD-induced NAFLD, by inhibiting the TLR-2 and TLR-4 signaling cascades.
참고문헌 (33)
- Ahsan H, "Prooxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin", Chemico-biological Interactions, 121, pp.161~175 (1999)
- Akira S, "Toll-like receptor signalling", Nature Reviews Immunology, 4, pp.499~511 (2004)
- Ammon HP, "Pharmacology of Curcuma longa", Planta Medica, 57, pp.1~7 (1991)
- Arrese M, "Innate immunity and inflammation in NAFLD", NASH, 2016, pp.61, 1294~1303
- Bacon BR, "Nonalcoholic steatohepatitis : An expanded clinical entity", Gastroenterology, 107, pp.1103~1109 (1994)
- Bieghs V, "The innate immune response during liver inflammation and metabolic disease", Trends in Immunology, 34, pp.446~452 (2003)
- Brunt EM, "Alcoholic and nonalcoholic steatohepatitis", Clinics in Liver Disease, 6, pp.399~420 (2002)
- 최성규, "우리 나라 남부지역에서 강황(Curcuma longa L.)의 생육특성", 한국약용작물학회지, 12(1), pp.85~88 (2004), 한국약용작물학회
- Csak T, "Deficiency in myeloid differentiation factor-2and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. American Journal of Physiology", Gastrointestinal and Liver Physiology, 300, pp.433~441 (2011)
- Farmer SR, "Transcriptional control of adipocyte formation", Cell Metabolism, 4, pp.263~273 (2006)
- Gervois P, "Regulation of lipid and lipoprotein metabolism by PPAR activators", Clinical Chemistry and Laboratory Medicine, 38, pp.3~11 (2000)
- Hardie DG, "AMP-activated", SNF1 protein kinases:Conserved guardians of cellular energy, 2007, pp.8, 774~785
- Herzig S, "AMPK: Guardian of metabolism and mitochondrial homeostasis", Nature Reviews Molecular Cell Biology, 19, pp.121~135 (2017)
- Kang OH, "Curcumin decreases oleic acid-induced lipid accumulation via AMPK phosphorylation in hepatocarcinoma cells", European Review for Medical and Pharmacological Sciences, 17, pp.2578~2586 (2013)
- Kesar V, "Toll-like receptors and liver disease", Liver International, 34, pp.184~196 (2013)
- Kim DS, "Curcuminoids from Curcuma longa L.(Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from βA(1–42) insult", Neuroscience Letters, 303, pp.57~61 (2001)
- Kim SB, "Hepatoprotective effect and synergism of bisdemethoycurcumin against MCD dietinduced nonalcoholic fatty liver disease in mice", PLoS One, 11, pp.e0147745~ (2016)[DOI]
- Kiziltas S, "TLR4 gene polymorphism in patients with nonalcoholic fatty liver disease in comparison to healthy controls", Metabolic Syndrome and Related Disorders, 12, pp.165~170 (2014)
- 이정훈, "Growth Characteristics of Turmeric (Curcuma longa L.) Germplasms and Storage Conditions of Seed Rhizomes", 한국약용작물학회지, 28(1), pp.47~55 (2020), 한국약용작물학회[DOI]
- Lee RG, "Nonalcoholic steatohepatitis : A study of 49patients", Human Pathology, 20, pp.594~598 (1989)
- 이영주, "유통 강황의 이산화황, 중금속 및 쿠르쿠민 함량", 한국약용작물학회지, 24(2), pp.121~128 (2016), 한국약용작물학회[DOI]
- Leevy CM, "Fatty liver: A study of 270 patients with biopsy proven fatty liver and a review of the literature", Medicine, 41, pp.249~278 (1962)
- Lu YC, "LPS", TLR4 signal transduction pathway, 2008, pp.42, 145~151
- Musi N, "AMP-activated protein kinase and type 2 diabetes", Current Medicinal Chemistry, 13, pp.583~589 (2006)
- O'Neill LAJ, "The family of five: TIRdomain-containing adaptors in Toll-like receptor signalling", Nature Reviews. Immunology, 7, pp.353~364 (2007)
- Pessayre D, "Mitochondria in steatohepatitis", Seminars in Liver Disease, 21, pp.57~70 (2001)
- Sahebkar A, "New peroxisome proliferator-activated receptor agonists : Potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease", Expert Opinion on Pharmacotherapy, 15, pp.493~503 (2014)
- Seki E, "Toll-like receptors and adaptor molecules in liver disease : Update", Hepatology, 48, pp.322~335 (2008)
- Tilg H, "Evolution of inflammation in nonalcoholic fatty liver disease : the multiple parallel hits hypothesis", Hepatology, 52, pp.1836~1846 (2010)
- Viollet B, "AMP-activated protein kinase in there gulation of hepatic energy metabolism : From physiology to therapeutic perspectives", Acta Physiologica, 196, pp.81~98 (2009)
- Wanless IR, "Fatty liver hepatitis(steatohepatitis)and obesity : An autopsy study with analysis of risk factors", Hepatology, 12, pp.1106~1110 (1990)
- Weng SY, "AMPK regulates macrophage polarization in adipose tissue inflammation and NASH", Journal of Hepatology, 58, pp.619~621 (2013)
- Yang Q, "Effects of soothing liver and invigorating spleen recipes on the mRNA and protein expression of TLR4in hepatic tissues of rats with NASH", Journal of Chinese Medicinal Materials, 36, pp.78~84 (2013)